132 related articles for article (PubMed ID: 35149547)
1. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
[TBL] [Abstract][Full Text] [Related]
2. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
[TBL] [Abstract][Full Text] [Related]
3. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
[TBL] [Abstract][Full Text] [Related]
4. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
[TBL] [Abstract][Full Text] [Related]
5. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B
J Clin Oncol; 2012 Feb; 30(4):372-9. PubMed ID: 22203755
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Nakamura K; Karmokar A; Farrington PM; James NH; Ramos-Montoya A; Bickerton SJ; Hughes GD; Illidge TM; Cadogan EB; Davies BR; Dovedi SJ; Valge-Archer V
Clin Cancer Res; 2021 Aug; 27(15):4353-4366. PubMed ID: 34011558
[TBL] [Abstract][Full Text] [Related]
7. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
8. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-
Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E
J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518
[TBL] [Abstract][Full Text] [Related]
9. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
Del Conte G; Sessa C; von Moos R; Viganò L; Digena T; Locatelli A; Gallerani E; Fasolo A; Tessari A; Cathomas R; Gianni L
Br J Cancer; 2014 Aug; 111(4):651-9. PubMed ID: 25025963
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
12. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract][Full Text] [Related]
13. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
14. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
[TBL] [Abstract][Full Text] [Related]
15. The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Dellavedova G; Decio A; Formenti L; Albertella MR; Wilson J; Staniszewska AD; Leo E; Giavazzi R; Ghilardi C; Bani MR
Cancer Res Commun; 2023 Mar; 3(3):489-500. PubMed ID: 36994441
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
Hong CR; Buckley CD; Wong WW; Anekal PV; Dickson BD; Bogle G; Hicks KO; Hay MP; Wilson WR
Radiother Oncol; 2022 Jan; 166():162-170. PubMed ID: 34861268
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
18. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
20. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
